UBS Lowers Price Target On Regeneron Pharmaceuticals, Inc. (REGN).

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. UBS has maintained its Neutral rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and reduced its price objective from $633 to $560 on June 5, noting mixed corporate updates and recent pipeline advancements.

A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality.

The Phase 2 COURAGE study interim readout, the Phase 3 AERIFY-1/2 trials results for itepekimab in COPD, the $256 million acquisition of 23andMe, and a license agreement with Hansoh for the ex-China rights to a Phase 3 GLP-1/GIP receptor agonist are among the noteworthy developments. UBS identifies Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s Eylea franchise’s ongoing weakening as a major short-term concern.

Recent strategic actions by Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), including licensing agreements and acquisitions, demonstrate that the company is expanding beyond its traditional ophthalmology portfolio. However, due to the difficulties the Eylea franchise is facing, market sentiment remains wary.

Although pipeline updates, such as the data from the COPD trial and the metabolic asset partnership with Hansoh, have long-term potential, UBS believes that these benefits are outweighed by the pressure from existing franchises, which supports the updated price target and Neutral position.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.